Literature DB >> 8148155

A heparin-binding form of placenta growth factor (PlGF-2) is expressed in human umbilical vein endothelial cells and in placenta.

S Hauser1, H A Weich.   

Abstract

Placenta Growth Factor (PlGF) was recently discovered as a secreted growth factor for vascular endothelial cells and based on its homology to vascular endothelial growth factor (VEGF), can be classified as a new member of this growth factor family. We have carried out polymerase chain amplification (PCR) of RNA from human umbilical vein endothelial cells and placenta tissue and discovered a second species of PlGF, PlGF-2. PlGF-2 has a 21-amino acid insertion not present in PlGF-1 coding for a highly basic region near the C-terminus. This is similar to VEGF189. Northern analysis has shown, that the PlGF gene is expressed only in a limited number of cell types and tissues, e.g. human umbilical vein endothelial cells (HUVE) and placenta. Infection of Sf158 insect cells with recombinant baculoviruses specific for the two forms showed, that both, PlGF-1 and PlGF-2 are secreted efficiently into the supernatant and PlGF-2 can bind with high affinity to heparin. Both PlGF forms had a similar mitogenic potency for bovine aortic endothelial cells. Binding studies with 125I-VEGF165 demonstrate, that supernatant of PlGF expressing insect cells can compete for receptor binding. Similar to VEGF, PlGF can exist in different forms which are probably generated by differential splicing. The occurrence of two molecular forms of this endothelial specific growth factor suggests different physiological roles of the two forms during placental development and differentiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8148155     DOI: 10.3109/08977199308991586

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  42 in total

1.  Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity.

Authors:  I Lang; C Hoffmann; H Olip; M A Pabst; T Hahn; G Dohr; G Desoye
Journal:  Cell Prolif       Date:  2001-06       Impact factor: 6.831

2.  De novo hem- and lymphangiogenesis by endothelial progenitor and mesenchymal stem cells in immunocompetent mice.

Authors:  Kerstin Buttler; Muhammad Badar; Virginia Seiffart; Sandra Laggies; Gerhard Gross; Jörg Wilting; Herbert A Weich
Journal:  Cell Mol Life Sci       Date:  2013-09-01       Impact factor: 9.261

3.  The placenta growth factor gene of the mouse.

Authors:  T DiPalma; M Tucci; G Russo; D Maglione; C T Lago; A Romano; S Saccone; G Della Valle; L De Gregorio; T A Dragani; G Viglietto; M G Persico
Journal:  Mamm Genome       Date:  1996-01       Impact factor: 2.957

4.  Placenta growth factor (PlGF) mRNA expression in brain tumors.

Authors:  M Nomura; S Yamagishi; S Harada; T Yamashima; J Yamashita; H Yamamoto
Journal:  J Neurooncol       Date:  1998-11       Impact factor: 4.130

Review 5.  Embryonic angiogenesis: a review.

Authors:  J Wilting; B Christ
Journal:  Naturwissenschaften       Date:  1996-04

6.  What is the role of vascular endothelial growth factor-related molecules in tumor angiogenesis?

Authors:  R F Nicosia
Journal:  Am J Pathol       Date:  1998-07       Impact factor: 4.307

Review 7.  New insights into molecular mechanisms of diabetic kidney disease.

Authors:  Shawn S Badal; Farhad R Danesh
Journal:  Am J Kidney Dis       Date:  2014-02       Impact factor: 8.860

Review 8.  Oxidative stress in the placenta.

Authors:  Leslie Myatt; Xiaolan Cui
Journal:  Histochem Cell Biol       Date:  2004-07-10       Impact factor: 4.304

9.  Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia.

Authors:  B Witzenbichler; T Asahara; T Murohara; M Silver; I Spyridopoulos; M Magner; N Principe; M Kearney; J S Hu; J M Isner
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

Review 10.  PlGF: a multitasking cytokine with disease-restricted activity.

Authors:  Mieke Dewerchin; Peter Carmeliet
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.